Barclays lowered the firm’s price target on InMode to $29 from $32 and keeps an Overweight rating on the shares following the company’s Q2 pre-release. Management’s new outlook reflects continued slowness in end-market utilization for aesthetic procedures, driving slower system sales, the analyst tells investors in a research note. The firm reduced estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMD:
- InMode price target lowered to $16 from $21 at Canaccord
- InMode lowers FY24 revenue view to $485M-$495M from $485M-$495M
- InMode sees Q2 revenue $86.2M-$86.3M, consensus $116.58M
- InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024
- InMode (NASDAQ:INMD): An Opportunity for Potential Upward Revision